DNA TOPOISOMERASES & LATE CELL CYCLE CHECKPOINTS

DNA拓扑异构酶

• 批准号: 6327943
• 负责人: PAUL J SMITH
• 金额: $ 0.31万
• 依托单位: UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-01 至 2001-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6327943
• 关键词: biomedical equipment development; biomedical resource; human tissue; nucleic acids; proteins; technology /technique

The bis(2,6-dioxopiperazine), ICRF-193, is potent non-DNA damaging inhibitor of the decantenation activity of topoisomerase II. The mechanism of inhibition is being interpreted in terms of an ATP-modulated protein-clamp model. ICRF-193 inhibits cell division but allows cell cycle traverse and progression to polyploidy with a delay at the G2 checkpoint. We will use conventional FCM methods to examine cell cycle regulation in conjunction with the various cyclins, including A and B1 and fluorescence lifetime analysis will be performed on cellular-bound ICRF-123 to analyze its interaction with chromatin.

二(2，6-二氧基哌嗪)，ICRF-193，是一种有效的非DNA损伤药物 拓扑异构酶去天线活性的抑制剂II. 抑制的机制被解释为 三磷酸腺苷调节的蛋白质钳模型。ICRF-193抑制细胞分裂 但允许细胞周期遍历和发展为多倍体 在G2检查站延迟。我们将使用传统的FCM方法来 结合各种细胞周期蛋白检查细胞周期调节， 包括A和B1以及荧光寿命分析 在细胞结合的ICRF-123上进行，以分析其与 染色质。